APA (7th ed.) Citation

I, A., A, L., A, T., & E, B. (2019). Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press.

Chicago Style (17th ed.) Citation

I, Avgerinos, Liakos A, Tsapas A, and Bekiari E. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press, 2019.

MLA (8th ed.) Citation

I, Avgerinos, et al. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Dove Medical Press, 2019.